Methods for reducing an adverse immune response to a foreign antigen in a human subject with anti-cd4 antibodies or cd4-binding fragments thereof or cd4-binding molecules
AssigneeLiquidating Trust
InventorsPaul Ponath, Michael Rosenzweig, Lou Vaickus
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of inducing tolerance or reducing an immune response to a foreign antigen in a human subject. The methods include administering anti-CD4 antibodies or CD4-binding fragments thereof or CD4-binding molecules, and the foreign antigen to the human subject.
Claims50
A method of inducing tolerance or reducing an immune response of a human subject to a foreign antigen, the method comprising:
- treating said subject with a regimen, said regimen comprising:
- a) one or more administrations of an anti-CD4 antibody or a CD4-binding fragment thereof or a CD4-binding molecule to said subject;
- and
- b) one or more administrations of said foreign antigen to said subject,
- wherein during a tolerizing window, the total dose of said antibody administered is 30 mg/kg or less, or the total dose of said fragment administered is the biological equivalent of 30 mg/kg or less, and wherein said tolerizing window is 10 days or less.
A method of inducing tolerance or reducing an immune response of a human subject to a foreign antigen, the method comprising:
- treating said subject with a regimen, said regimen comprising:
- a) one or more administrations of an anti-CD4 antibody or a CD4-binding fragment thereof or CD4-binding molecule to said subject, the first administration comprising at least 0.05 mg/kg but less than 5 mg/kg of said antibody or the biological equivalent of said fragment;
- and
- b) one or more administrations of said foreign antigen to said subject.
A method of inducing tolerance or reducing an immune response to a foreign antigen in a human subject, said method comprising:
- treating said subject with a regimen, said regimen comprising:
- a) at least one administration of an anti-CD4 antibody or a CD4-binding fragment thereof or CD4-binding molecule;
- and
- b) at least one administration of said foreign antigen,
- wherein the minimum concentration of said antibody or fragment in the blood of said subject is not less than 5 μg/mL during a tolerizing window.
6-10. (canceled)
13-16. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.